Moderna’s FDA Trouble Signals Uncertainty in the Drug Regulation Landscape

On February 12th, the FDA refused to review Moderna’s mRNA-based influenza vaccine. This decision echoed through the life sciences sector, with many industry leaders viewing it as part of a concerning shift in the agency’s stance toward this promising technology.

mRNA vaccine platforms entered the global spotlight during the COVID-19 pandemic and served as the technological foundation for vaccines developed under Operation Warp Speed in President Donald Trump’s first term. Since then, investment in mRNA technology has surged. The platform enables the rapid development of vaccines against emergent viral strains in a fraction of the time required for traditional live-attenuated or inactivated vaccine approaches. 

However, during Trump’s second term, mRNA technologies have faced heightened scrutiny from U.S. regulatory bodies. In August 2025, the Department of Health and Human Services cut funding for 22 mRNA vaccine programs, affecting pharmaceutical leaders such as Pfizer, Moderna, Sanofi, and AstraZeneca.

The FDA’s issuance of a refusal-to-file letter to Moderna effectively prevented the influenza vaccine from even entering formal review. This decision marked a significant setback for the platform, and markets reacted swiftly: Moderna’s shares fell 9%, closing at $40.08. Biotech industry leaders widely interpreted the move as a troubling signal for emerging therapies, arguing that it reflected political pressure overriding established scientific conclusions.

The controversy heightened when it became known that the rejection letter was personally signed by Vinay Prasad, head of the Center for Biologics Evaluation and Research. Prasad appears to have overruled internal recommendations supporting acceptance of the application for review. For many observers, the decision heightened concerns about internal agency governance and an increasingly politicized regulatory stance. 

However, on February 18th, in another unexpected turn of events, the FDA decided to rescind the refusal-to-file letter issued against Moderna’s mRNA flu vaccine. This decision came just one week after the initial rejection, following closed-door meetings between the FDA and Moderna executives. Moderna CEO Stéphane Bancel released a statement saying, “We appreciate the FDA’s engagement in a constructive Type A meeting and its agreement to advance our application for review.” Investors responded positively, with Moderna shares rising 8.5% to $47.67 on the day of the announcement.

This reversal casts Moderna’s development pipeline in a more favorable light. The company’s mRNA influenza vaccine alone is projected to generate billions in annual revenue if approved. Since the pandemic-era surge in vaccine profits, Moderna has struggled to return to sustained profitability, making diversification beyond COVID-19 vaccines critical to its long-term financial stability.

Whether this episode represents a temporary disruption or a deeper shift in the regulatory climate surrounding mRNA technology remains an ongoing question. What is clear, however, is that the FDA’s handling of Moderna’s application has intensified debates over political influences on pharmaceutical regulation and cast uncertainty on the major players in the vaccine development sector.

In the end, innovation means nothing without approval.